全文获取类型
收费全文 | 5153篇 |
免费 | 292篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 133篇 |
妇产科学 | 203篇 |
基础医学 | 653篇 |
口腔科学 | 96篇 |
临床医学 | 545篇 |
内科学 | 989篇 |
皮肤病学 | 90篇 |
神经病学 | 324篇 |
特种医学 | 284篇 |
外科学 | 838篇 |
综合类 | 83篇 |
一般理论 | 6篇 |
预防医学 | 404篇 |
眼科学 | 149篇 |
药学 | 341篇 |
中国医学 | 28篇 |
肿瘤学 | 243篇 |
出版年
2022年 | 33篇 |
2021年 | 79篇 |
2020年 | 55篇 |
2019年 | 64篇 |
2018年 | 84篇 |
2017年 | 62篇 |
2016年 | 61篇 |
2015年 | 64篇 |
2014年 | 95篇 |
2013年 | 172篇 |
2012年 | 225篇 |
2011年 | 292篇 |
2010年 | 133篇 |
2009年 | 172篇 |
2008年 | 276篇 |
2007年 | 300篇 |
2006年 | 316篇 |
2005年 | 286篇 |
2004年 | 292篇 |
2003年 | 225篇 |
2002年 | 279篇 |
2001年 | 48篇 |
2000年 | 43篇 |
1999年 | 56篇 |
1998年 | 72篇 |
1997年 | 55篇 |
1996年 | 59篇 |
1995年 | 38篇 |
1994年 | 34篇 |
1993年 | 50篇 |
1992年 | 33篇 |
1991年 | 36篇 |
1990年 | 29篇 |
1989年 | 32篇 |
1987年 | 36篇 |
1986年 | 31篇 |
1985年 | 38篇 |
1984年 | 43篇 |
1983年 | 57篇 |
1982年 | 54篇 |
1981年 | 54篇 |
1980年 | 48篇 |
1979年 | 29篇 |
1978年 | 48篇 |
1977年 | 49篇 |
1976年 | 44篇 |
1975年 | 35篇 |
1974年 | 31篇 |
1973年 | 36篇 |
1972年 | 33篇 |
排序方式: 共有5456条查询结果,搜索用时 15 毫秒
991.
992.
Frances J Northington Raul Chavez-Valdez Ernest M Graham Sheila Razdan Estelle B Gauda Lee J Martin 《Journal of cerebral blood flow and metabolism》2011,31(1):178-189
Necrostatin-1 inhibits receptor-interacting protein (RIP)-1 kinase and programmed necrosis and is neuroprotective in adult rodent models. Owing to the prominence of necrosis and continuum cell death in neonatal hypoxia–ischemia (HI), we tested whether necrostatin was neuroprotective in the developing brain. Postnatal day (P)7 mice were exposed to HI and injected intracerebroventricularly with 0.1 μL of 80 μmol necrostatin, Nec-1, 5-(1H-Indol-3-ylmethyl)-(2-thio-3-methyl) hydantoin, or vehicle. Necrostatin significantly decreased injury in the forebrain and thalamus at P11 and P28. There was specific neuroprotection in necrostatin-treated males. Necrostatin treatment decreased necrotic cell death and increased apoptotic cell death. Hypoxia–ischemia enforced RIP1–RIP3 complex formation and inhibited RIP3–FADD (Fas-associated protein with death domain) interaction, and these effects were blocked by necrostatin. Necrostatin also decreased HI-induced oxidative damage to proteins and attenuated markers of inflammation coincidental with decreased nuclear factor-κB and caspase 1 activation, and FLIP ((Fas-associated death-domain-like IL-1β-converting enzyme)-inhibitory protein) gene and protein expression. In this model of severe neonatal brain injury, we find that cellular necrosis can be managed therapeutically by a single dose of necrostatin, administered after HI, possibly by interrupting RIP1–RIP3-driven oxidative injury and inflammation. The effects of necrostatin treatment after HI reflect the importance of necrosis in the delayed phases of neonatal brain injury and represent a new direction for therapy of neonatal HI. 相似文献
993.
994.
995.
996.
Joseph F. Sucher Frederick A. Moore R. Matthew Sailors Ernest A. Gonzalez Bruce A. McKinley 《World journal of surgery》2010,34(2):216-222
Background
A computerized protocol was developed and used to standardize bedside clinician decision making for resuscitation of shock due to severe trauma during the first day in the intensive care unit (ICU) at a metropolitan Level I trauma center. We report overall performance of a computerized protocol for resuscitation of shock due to severe trauma, incorporating two options for resuscitation monitoring and intervention intensity, according to: (1) duration of use and (2) acceptance of computerized protocol-generated instructions. 相似文献997.
Luca Ansaloni Roland E Andersson Franco Bazzoli Fausto Catena Vincenzo Cennamo Salomone Di Saverio Lorenzo Fuccio Hans Jeekel Ari Leppäniemi Ernest Moore Antonio D Pinna Michele Pisano Alessandro Repici Paul H Sugarbaker Jean-Jaques Tuech 《World journal of emergency surgery : WJES》2010,5(1):1-10
Background
Obstructive left colon carcinoma (OLCC) is a challenging matter in terms of obstruction release as well of oncological issues. Several options are available and no guidelines are established. The paper aims to generate evidenced based recommendations on management of OLCC.Methods
The PubMed and Cochrane Library databases were queried for publications focusing on OLCC published prior to April 2010. A extensive retrieval, analyses, and grading of the literature was undertaken. The findings of the research were presented and largely discussed among panellist and audience at the Consensus Conference of the World Society of Emergency Surgery (WSES) and Peritoneum and Surgery (PnS) Society held in Bologna July 2010. Comparisons of techniques are presented and final committee recommendation are enounced.Results
Hartmann's procedure should be preferred to loop colostomy (Grade 2B). Hartmann's procedure offers no survival benefit compared to segmental colonic resection with primary anastomosis (Grade 2C+); Hartmann's procedure should be considered in patients with high surgical risk (Grade 2C). Total colectomy and segmental colectomy with intraoperative colonic irrigation are associated with same mortality/morbidity, however total colectomy is associated with higher rates impaired bowel function (Grade 1A). Segmental resection and primary anastomosis either with manual decompression or intraoperative colonic irrigation are associated with same mortality/morbidity rate (Grade 1A). In palliation stent placement is associated with similar mortality/morbidity rates and shorter hospital stay (Grade 2B). Stents as a bridge to surgery seems associated with lower mortality rate, shorter hospital stay, and a lower colostomy formation rate (Grade 1B).Conclusions
Loop colostomy and staged procedure should be adopted in case of dramatic scenario, when neoadjuvant therapy could be expected. Hartmann's procedure should be performed in case of high risk of anastomotic dehiscence. Subtotal and total colectomy should be attempted when cecal perforation or in case of synchronous colonic neoplasm. Primary resection and anastomosis with manual decompression seems the procedure of choice. Colonic stents represent the best option when skills are available. The literature power is relatively poor and the existing RCT are often not sufficiently robust in design thus, among 6 possible treatment modalities, only 2 reached the Grade A. 相似文献998.
999.
1000.
Yi T Elson P Mitsuhashi M Jacobs B Hollovary E Budd TG Spiro T Triozzi P Borden EC 《Oncotarget》2011,2(12):1155-1164
Since sodium stibogluconate (SSG) inhibited phosphatases including SHP-1 and augmented anti-tumor actions of IFN-α2b in vitro and in mice, two Phase I trials of SSG/IFN-α2b combination were undertaken to evaluate safety and target inhibition. Escalating doses of SSG (200-1200 mg/m2) and fixed doses of IFN-α2b (3x106 units/m2) with or without chemotherapy (dacarbazine, vinblastine, cisplatin) were evaluated for side effects and impact on SHP-1 phospho-substrates and IFNα-stimulated-genes (ISGs) in peripheral blood in 40 patients with metastatic melanoma, soft tissue sarcomas, gastrointestinal stromal tumors, and breast or colorectal carcinomas who did not have other established treatment options. Common adverse events were bone marrow suppression, fatigue, gastrointestinal upset, and asymptomatic lipase elevation (n=13); the latter was dose related and mostly after 10d of SSG/IFN-α2b in combination. Levels of SHP-1 substrates (pSTAT1, pSTAT3, pLck and pSlp76) were increased (up to 3x) in peripheral blood cells following SSG with no potentiation by combination with IFN-α2b. Representative ISGs in peripheral blood were induced after IFN-α2b at 4 and 24 hrs with selective modulations by combination. The median time on trials was 2.3 months (10-281d) with no objective regression of disease. Alive at 1y were 17/40 (43%) patients and after 2y were 8/40 (20%) following treatment initiation. These data demonstrate that SSG impacted signal molecules consistent with PTP inhibition and was tolerated in combination with IFN-α2b. Phase II investigations of SSG could safely utilize doses of up to 1200 mg/m2 of SSG for up to 10d alone or in combination with IFN-α2b with or without chemotherapy. 相似文献